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The 2001 Bethesda System for Reporting Cervical Cytology[1] 
represents the latest international consensus for classifying cervical 
cytology. In terms of this typology, the finding ‘atypical glandular 
cells’ (AGC) indicates ‘morphological changes that exceed those 
normally expected but that are not sufficient to suggest a diagnosis of 
adenocarcinoma in situ’ (AIS).[1]
AGC is an uncommon cytological interpretation, occurring in 
<0.5% of routine Pap tests.[2-4] Given its rarity and the manifold 
sources of glandular cells, an AGC diagnosis is associated with a 
high level of interobserver variability and manifold differential 
diagnoses.[5] However, a cytological diagnosis of AGC is associated 
with an increased risk of premalignant and invasive lesions.[2,6,7] To 
our knowledge, there have been no studies published in the English 
language literature correlating AGC classification with histological 
diagnosis in South African (SA) patients. Our study may therefore be 
relevant in the SA context, given that cervical carcinoma remains the 
most common cancer of women in Africa, with an age-standardised 
mortality rate of 21.0% compared with a worldwide mortality rate 
of 8.9%.[8] SA is characterised by a high prevalence of HIV infection 
and low cervical screening rates.[8] Current research estimates that 
the proportion of HIV-positive patients in Cape Town undergoing 
at least one Pap test is 13.1%,[8] while <10% of HIV-negative women 
utilise the available screening programmes.[9]
Objectives
Primarily, to correlate definitive histological findings following 
a suspicious Pap test diagnosed as AGC and to summarise these 
findings, given the available data. Secondly, to compare the data 
from Groote Schuur Hospital (GSH), Cape Town, with similar 
international studies[10] with the intention of comparing local findings 
with other published results. Throughout the study, patterns that 
may improve management of AGC and/or suggest future research, 
especially in low-resource settings, were sought.
Methods
A retrospective audit of all Pap tests diagnosed as AGC on cervical 
cytology and subsequent histological investigations performed by the 
National Health Laboratory Service at GSH was undertaken for the 
period 17 February 2003 - 31 December 2014.
Similar audits as well as studies that explored the clinical 
significance of AGC were identified using a Medline/PubMed search 
of the English literature from 1988 to 2015. The search criteria 
included, but were not limited to, the terms ‘atypical glandular cells’, 
‘AGC’, ‘AGUS’, ‘atypical glandular cells and HPV’ and ‘management of 
atypical glandular cells’.
The total number of patients who received Pap tests over the 
period 2003 - 2014 was estimated by extracting all Pap test reports 
from the laboratory information software, Disa*Lab (Laboratory 
System Technologies, SA) in the anatomical pathology laboratory at 
GSH and then merging the records with the same identity numbers. 
Where identity numbers were unavailable, Pap test results that shared 
hospital number and date of birth were merged to form a single record. 
Records with no associated histological investigations (167/424) were 
removed, as were samples deemed insufficient by the pathologist 
(9/424) and entries with no recorded age (1/424). Recurrent AGC 
diagnoses over the period of investigation were present (10/424), and 
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these records were merged and identified 
accordingly. Following this procedure, there 
were 237 patients with AGC cytological 
diagnoses and corresponding histological 
diagnoses suitable for analysis. In many 
cases, information regarding HIV status, 
menopausal classification, postmenopausal 
bleeding, contraception method, parity, 
sample adequacy, reason for Pap test, 
presence of pathogens and condition of the 
cervix at time of Pap test were selectively 
recorded. In cases where menopausal 
status was not indicated, the age of 50 
years was considered to be a proxy for 
menopause. In addition, if patient records 
indicated postmenopausal bleeding but 
no menopausal status was provided, these 
women were inferred to be postmenopausal.
Where histological results relating to the 
same cytological finding described differ ent 
pathology in a uterine or extra uterine site at 
different points in time, these pathologies 
were recorded in the order of their diagnosis. 
However, for the purposes of allocating a 
distinct diagnostic label to each patient, 
the most clinically significant diagnosis 
was used. Lesions classified histologically 
as normal, benign or inflammatory were 
grouped together. Discrete diagnostic classi-
fications were created for low-grade squa-
mous intraepithelial lesions (LSIL), high-
grade squamous intraepithelial lesions 
(HSIL), AIS, cervical carcinoma, endo metrial 
hyperplasia (EH), endometrial carcinoma 
and other (extrauterine) malig nancy. Signifi-
cant pathology was defined to mean a 
histological diagnosis of CIN2+ (CIN2/3/
AIS), EH or carcinoma.
The current protocol at GSH does not 
include routine testing for human papilloma-
virus (HPV) genotypes. However, the 
diagnosis of HSIL and any form of cervical 
carcinoma strongly suggests infection with 
high-risk HPV,[4] and where these diagnoses 
were available they were used as a proxy for 
infection with high-risk HPV.
The data analysed are included below. 
Where differences in proportions of cate-
gorical variables were computed, Fisher’s exact 
test was used. Comparisons with a p-value 
of <0.05 were deemed to be statistically 
significant. Statistical analysis was performed 
using R version 2.15.3 (R Foundation for Stati-
stical Computing, Austria). Ethics approval 
was obtained from the Human Research 
Ethics Committee, University of Cape Town 
(HREC Ref: 406/2015).
Results
An estimated 410 867 patients received Pap 
tests over the study period, of which 424 
(0.1%) were classified as AGC on cervical 
cytology. Table 1 sets out the corresponding 
histological diagnoses recorded for the 237 
cases that were suitable for analysis.
Of the 237 women diagnosed with AGC on 
cervical cytology, 120 (50.6%) were diag nosed 
with significant clinical disease. Importantly, 
76 of the diagnoses in this group (32.1% of the 
total) were classified as malignancies.
Of AGC diagnoses at GSH, 86 lesions 
(36.3%) were found to be squamous in origin 
on histological examination, as opposed to 
61 glandular lesions (25.7%).
There was one case of extrauterine patho logy 
(0.4%), namely vaginal malignancy. Seven of 
the uterine carcinomas (3.0% of the total) 
were identified histologically as Müllerian 
mixed tumours. 
Data from this study were compared 
with aggregated data from 24 international 
studies[10] using similar diagnostic criteria. 
We summarise this comparison in Table 2.
Age
The mean age of patients in the study was 
50.5 years (standard deviation 13.6, median 
49.0, range 25 - 91); 120 women (50.6%) 
were aged <50 years and 117 (49.4%) 
≥50  years. The age distribution of women 
with an AGC diagnosis and subsequent 
histological correlation at GSH is shown in 
Fig. 1. A linear trend line was superimposed 
for endometrial carcinoma (R2=0.84), while 
polynomial regression was used to fit lines 
for HSIL (R2=0.72) and cervical carcinoma 
(R2=0.93).
In the GSH group, the incidence of CIN2+ 
lesions peaked at age 40 years (mean 41.8), 
while the prevalence of cervical carcinoma 
was highest at 49 years (mean 50.1) and that 
of endometrial carcinoma at 65 years (mean 
65.2). An age of ≥50 years was predictive of 
significant pathology (odds ratio (OR) 2.39, 
Table 1. Histological diagnoses in patients 
with a cytological diagnosis of AGC
Histological diagnosis n (%)
Benign 82 (36.4)
LSIL 35 (14.8)
HSIL (CIN2+) 40 (16.9)
Cervical AIS 2 (0.8)
Cervical Ca. 28 (11.8)
Endometrial Ca. 47 (19.8)
EH 2 (0.8)
Vaginal Ca. 1 (0.4)
Total 237 (100.0)
Ca. = carcinoma.
Table 2. Comparison of the histological findings of AGC Pap tests referenced in 
aggregated international data[10] with data collected at GSH from 2003 to 2014
Outcome International data,% (range)[10] GSH data, % Variance
Prevalence of AGC 0.3 (0.1 - 6.0) 0.1 0.2
AGC Pap with histology 57.0 (36.3 - 100.0) 56.0 1.0
AIS 2.9 (0.0 - 15.7) 0.8 2.0
EH 1.4 (0.0 - 11.8) 0.8 0.5
Malignancy 5.2 (0.0 - 15.5) 32.1 26.9
HSIL 11.1 (1.5 - 46.7) 16.9 5.8

























Fig. 1. Histological diagnosis by age band in women with a cytological diagnosis of AGC. (Ca. = 
carcinoma; Poly. = polynomial regression.)
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95% confidence interval 1.38 - 4.12; p<0.001).
Fig. 2 summarises the distribution of histo-
logical diagnoses in women aged <50 years 
and those aged ≥50 years.
In addition to the age data, quantitative 
information regarding menopausal classi-
fication, postmenopausal bleeding, recurrent 
AGC diagnoses, HIV status, condition of 
the cervix, sample adequacy, presence of 
the transformation zone (TZ), reason for 
the Pap test, presence of non-HIV/HPV 
pathogens, parity and contraception method 
was collected. Results of these findings are 
summarised in Tables 3 and 4. In each table 
only outcomes classified as benign, HSIL, 
AIS, cervical or endometrial carcinoma are 
detailed explicitly. The column headed ‘Other 
Dx.’ presents the residuals for all diagnoses 
that did not fall into the groups previously 
specified. Each risk group was broken 
down as a percentage of total AGC Pap 
tests (N=237) and followed by a breakdown 
of histological diagnoses according to the 
number of women per risk category.
Menopausal status and postmenopausal 
bleeding. Histological outcomes according 
to menopausal status and postmenopausal 
bleeding are set out in Table 3.
Recurrent AGC diagnoses. Recurrent 
AGC diagnoses appeared to increase the 
risk of significant pathology (OR 1.48), 
but this increase was not statistically 
significant.
Condition of cervix, classification of 
sample and absence of the TZ. The clinical 
condition of the cervix as ‘suspected carci-
noma’ appeared to be a predictor of endo-
metrial carcinoma in the study population. 
Likewise, the classification of a histological 
sample as unsatisfactory appeared to be 
predictive of endometrial carcinoma, as did 
absence of the TZ.
HPV infection. Seventy women (29.5%) 
were diagnosed with HSIL or cervical 
malignancy and were therefore suspected to 
be positive for high-risk HPV DNA.
Presence of non-HIV/HPV sexually trans-
mitted pathogens. Bacterial infection or 
the suggested presence of Candida species, 
Gardnerella vaginalis, herpes simplex virus, 
Chlamydia or Trichomonas vaginalis was 
recorded. The prevalence of HSIL or cervical 
carcinoma was 31.9% in women infected 
with at least one pathogen v. 29.1% in non-
infected women.
Parity. The prevalence of HSIL or cervical 
carcinoma in multiparous women was 32.3% 
v. 16.7% in women reported to have borne at 
most one child.
Contraception. The prevalence of HSIL or 
cervical carcinoma was 45.9% among women in 
the GSH group using hormonal contraception v. 
38.1% in women using no contraception.
Discussion
In the GSH population of women reported to 
have AGC on cervical cytology, histological 
findings confirmed significant pathology in 
the majority of cases.
Women aged ≥50 years were 2.39 times 
more likely to have significant pathology 
than women aged <50 years. Other predic-
tive factors were postmenopausal bleeding, 
recurrent AGC diagnoses, HIV infection, 
the presence of sexually transmitted patho-
gens, multiparity, hormonal contraception, 
absence of the TZ and suspicion of carcino-
ma on macroscopic assessment of the cervix.
Age is recognised as an important risk 
factor in the development of significant 
pathology.[4] The GSH data reflect the natural 
histories of both cervical and endometrial 
carcinomas, with the latter being nearly 23 
times more prevalent in the study population 
after 50 years of age. Furthermore, the GSH 
data are aligned with reports suggesting that 
the development of cervical/endometrial 
carcinoma takes several years to decades 
to progress from preneoplastic disease to 
invasive carcinoma.[4,11] The ratio of squamous 
to glandular lesions appears consistent with 
that reported in the literature.[2,4,11]
Postmenopausal bleeding has been shown 
to predict invasive pathology in women aged 
>50 years.[2] These findings were confirmed 
in the GSH population, where women with 
Table 3. Histological outcomes in women with a cytological diagnosis of AGC, according to menopausal status and postmenopausal bleeding
Risk factor
AGC Dx.
(N=237), % Benign, % HSIL, % AIS, % Cerv Ca., % Endo Ca., % Other Dx., %
Menopausal status
Premenopausal 48.5 18.1 11.8 0.8 5.9 0.0 63.4
Postmenopausal 51.5 32.0 9.8 0.0 11.5 38.5 8.2
Postmenopausal bleeding
Present 11.0 46.2 0.0 0.0 3.8 42.3 7.7
Absent 3.8 11.1 66.7 0.0 11.1 11.1 0.0
NA 85.2 34.2 16.8 1.0 12.9 17.3 17.8
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Fig. 2. Histological diagnosis by age band (<50 and ≥50 years) in women with a cytological diagnosis 
of AGC. (Ca. = carcinoma.)
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postmenopausal bleeding were three times 
more likely to have significant pathology 
than postmenopausal women who were not 
experiencing such bleeding.
The prevalence of HIV in SA is estimated 
to be 12.2% (5.0% in the Western Cape),[12] so 
the incomplete data in respect of HIV status 
are likely to include several HIV-posi tive 
women. Patients with HIV have an increased 
absolute risk of an AGC diagnosis. [3] Further-
more, HIV-positive women are five times 
more likely to be infected with HPV than 
HIV-negative women,[3,9] which provides a 
plausible explana tion for the higher incidence 
of squamous cervical lesions in the GSH 
group.
It is generally agreed that HPV is the agent 
that causes cervical neoplasia.[4,9,13] There are 
Table 4. Histological outcomes in women with a cytological diagnosis of AGC, according to Pap test, HIV status, presence of non-
HIV/HPV pathogens, parity and method of contraception
Risk factor
AGC Dx.
(N=237), % Benign, % HSIL, % AIS, % Cerv Ca., % Endo Ca., % Other Dx., %
Recurrent AGC diagnosis
Yes 4.2 30.0 20.0 0.0 20.0 20.0 10.0
No 95.8 34.8 16.7 0.9 11.5 19.8 16.3
Cervical condition
Healthy 43.0 43.1 15.7 2.0 7.8 17.6 13.8
Inflammatory 9.3 36.4 27.3 0.0 18.2 9.1 9.0
Suspect Ca. 7.6 22.2 0.0 0.0 22.2 50.0 5.6
NA 40.1 27.4 18.9 0.0 12.6 18.9 22.2
Adequacy
Satisfactory 85.7 36.5 17.2 1.0 11.8 16.7 16.8
Unsatisfactory 10.1 25.0 16.7 0.0 16.7 37.5 4.1
NA 4.2 20.0 10.0 0.0 0.0 40.0 30.0
TZ
Present 92.8 35.9 17.3 0.9 11.8 17.3 16.8
Absent 5.5 7.7 15.4 0.0 15.4 61.5 0.0
NA 1.7 50.0 0.0 0.0 0.0 25.0 25.0
Reason for Pap test
Screening 31.6 32.0 26.7 2.7 10.7 10.7 17.2
Diagnostic 26.2 43.5 6.5 0.0 11.3 25.8 12.9
NA 42.2 31.0 16.0 0.0 13.0 23.0 17.0
HIV
Positive 6.8 31.2 43.8 6.2 18.8 0.0 0.0
Negative 22.4 45.3 13.2 0.0 5.7 24.5 11.3
NA 70.9 31.5 15.5 0.6 13.1 20.2 19.1
Non-HIV/HPV pathogens
Present 29.1 33.3 29.0 0.0 2.9 10.1 24.7
Absent 67.9 35.4 12.4 1.2 15.5 23.6 11.9
NA 3.0 28.6 0.0 0.0 14.3 28.6 28.5
Multiparity
Yes 14.3 38.2 17.6 0.0 14.7 20.6 8.9
No 2.5 33.3 0.0 0.0 16.7 0.0 50.0
NA 83.1 34.0 17.3 1.0 11.2 20.3 16.2
Contraception
Condom 0.4 100.0 0.0 0.0 0.0 0.0 0.0
None 26.6 28.6 17.5 0.0 20.6 23.8 9.5
Hormonal 10.1 37.5 37.5 4.2 4.2 0.0 16.6
Tubal ligation 2.5 83.3 16.7 0.0 0.0 0.0 0
NA 60.3 34.3 13.3 0.7 9.8 22.4 19.5
Dx. = diagnosis; Cerv Ca. = cervical carcinoma; Endo Ca. = endometrial carcinoma; NA = not available.
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over 100 recognised genotypes of HPV, but types 16 and 18 account 
for approximately 70% of cases of CIN.[13] Research also suggests 
that HPV DNA testing is useful to differentiate between cervical 
and endometrial lesions[4] and that infection with HPV increases a 
woman’s risk of cervical pathology significantly. [9] Local studies in 
women with atypical cervical cytology have estimated the prevalence 
of high-risk HPV at 54.3%.[14] The estimated prevalence of high-risk 
HPV in the GSH data would therefore be expected to be closer to the 
reported local prevalence, and this represents a serious limitation in 
the analysis of the GSH data.
The GSH data point to an increased risk of HPV-associated cervical 
lesions in women infected with sexually transmitted pathogens. 
Research suggests that co-infection with HPV and other sexually 
transmitted diseases increases the risk of cervical carcinoma.[9] In the 
GSH study, the risk of HSIL or cervical carcinoma in women with 
an AGC diagnosis was higher among those who tested positive for 
sexually transmitted pathogens.
There was an increased prevalence of HSIL and cervical carcinoma 
among multiparous women in the GSH study, which is consistent 
with published research.[9]
Continuous use of oral contraceptives for >5 years has been shown 
to increase the risk of significant cervical pathology.[9] Women in 
the GSH study using hormonal contraception did have an increased 
prevalence of such pathology, but any further inference was limited 
given that the duration of use of hormonal contraceptives was 
not recorded on the database. The explanation for the increase 
in endometrial carcinoma in women not using contraception is 
probably age-related, given that postmenopausal women do not 
require contraception.
The study findings suggest that the prevalence of AGC in the 
GSH population is within the range described in the international 
literature.[10] The notably higher proportion of malignancies in the 
GSH data is probably a result of current protocol regarding Pap 
testing in the public health system, coupled with a high burden of 
HIV/HPV infection in SA. Currently the National Department of 
Health offers asymptomatic women three free Pap tests at 10-year 
intervals from 30 years of age.[9,15] It is clear, however, that most SA 
women have never had a Pap test,[9] and this lack of population-based 
screening and treatment facilitates long-term HPV infection, which 
poses the single largest risk for cervical carcinoma[15] and probably 
explains the elevated comparative risk of malignancy encountered 
in poor countries,[9] as observed in the GSH data. In low-resource 
settings such as SA, where utilisation of Pap tests is low, HPV 
genotyping should be considered as a screening method, especially 
in younger women, given that absence of high-risk HPV DNA 
renders the risk of significant disease negligible for some time.[15,16] 
This would facilitate longer screening intervals, with an associated 
reduction in screening costs and benefits to patients.
Research has shown that the sensitivity of HPV DNA testing is 
equivalent to that of cytological screening and that it may be easier to 
implement.[17] In this regard, the introduction of point-of-care HPV 
DNA testing using the GeneXpert (Cepheid, USA) cartridge-based 
system holds some promise. This qualitative real-time polymerase 
chain reaction assay tests for 14 high-risk HPV genotypes in about 
1 hour and exhibits clinical performance comparable to current batch 
HPV DNA testing, which takes several hours to complete.[18] As a 
consequence of SA’s high prevalence of HIV and a burdened public 
health system, the incidence of tuberculosis and HPV is high. [18] 
The National Department of Health has embarked on a national 
programme for detecting tuberculosis using the GeneXpert MTB/RIF 
assay.[18] The infrastructure already in place could be simultaneously 
deployed to run GeneXpert HPV assays as a primary screening tool 
or an adjunct to cervical cytology.[18] While this proposal merits 
further investigation with regard to cost and feasibility, point-of-care 
testing would be beneficial in terms of reducing losses to follow-up in 
the SA public health sector, where the turnaround time for a Pap test 
is currently around 6 weeks.
Conclusion
In the GSH setting, AGC is a rare but important finding, indicating 
significant pathology in a majority of cases, with rates of malignancy 
higher than those found in comparable international investigations. [10] 
The findings of the GSH study suggest that when AGC is diagnosed 
in women aged >50 years, colposcopy and endometrial sampling 
are indicated. However, in women diagnosed with AGC aged 
<50 years and who are HIV- and HPV-negative, more conservative 
management could be considered in the form of more frequent Pap 
tests and/or HPV genotyping rather than immediate colposcopy.
Acknowledgement. The authors are grateful for valuable input from 
Prof. L Denny, head of the Gynaecological Cancer Research Centre 
(funded by the South African Medical Research Council).
1. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: Terminology for reporting results of 
cervical cytology. JAMA 2002;287(16):2114-2119. DOI:10.1001/jama.287.16.2114
2. Schorge JO, Rauh-Hain JA. Atypical glandular cells. Clin Obstet Gynecol 2013;56(1):35-43. 
DOI:10.1097/GRF.0b013e3182823849
3. Massad LS, Xie X, Darragh TM, et al. Histologic correlates of glandular abnormalities in cervical 
cytology among women with human immunodeficiency virus. Obstet Gynecol 2009;114(5):1063-
1068. DOI:10.1097/AOG.0b013e3181bc6ce0
4. Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Kinney W. Relationship of atypical glandular cell 
cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks. Obstet 
Gynecol 2010;115(2):243-248. DOI:10.1097/AOG.0b013e3181c799a3
5. Confortini M, di Bonito L, Carozzi F, et al. Interlaboratory reproducibility of atypical glandular cells 
of undetermined significance: A national survey. Cytopathology 2006;17(6):353-360. DOI:10.1111/
j.1365-2303.2006.00372.x
6. Duska LR. Can we improve the detection of glandular cervical lesions: The role and limitations of 
the Pap smear diagnosis atypical glandular cells (AGC). Gynecol Oncol 2009;114(3):381-382. 
DOI:10.1016/j.ygyno.2009.07.008
7. Zhao C, Florea A, Onisko A, Austin RM. Histologic follow-up results in 662 patients with Pap 
test findings of atypical glandular cells: Results from a large academic women’s hospital laboratory 
employing sensitive screening methods. Gynecol Oncol 2009;114(3):383-389. DOI:10.1043/2008-
0755-OAR1.1
8. Batra P, Kuhn L, Denny L. Utilisation and outcomes of cervical cancer prevention services among HIV-
infected women in Cape Town. S Afr Med J 2010;100(1):39-44.
9. Denny L. Prevention of cervical cancer. Reprod Health Matters 2008;16(32):18-31. DOI:10.1016/
S0968-8080(08)32397-0
10. Schnatz PF, Guile M, O’Sullivan DM, Sorosky JI. Clinical significance of atypical glandular cells on 
cervical cytology. Obstet Gynecol 2006;117(3):701-708. DOI:10.1097/01.AOG.0000202401.29145.68
11. Wang SS, Sherman ME, Hildesheim A, et al. Cervical adenocarcinoma and squamous cell carcinoma 
incidence trends among white women and black women in the United States for 1976-2000. Cancer 
2004;100(5):1035-1044. DOI:10.1002/cncr.20064
12. Shisana O, Rehle T, Simbayi LC, et al. South African National HIV Prevalence, Incidence and 
Behaviour Survey, 2012. Cape Town: HSRC Press, 2014:xxiii-xxiv.
13. Kumar V, Abbas AK, Aster J, eds. Robbins Basic Pathology. 9th ed. Philadelphia: Elsevier, 2013:685-
689.
14. Richter K, Becker P, Horton A, Dreyer G. Age-specific prevalence of cervical human papillomavirus 
infection and cytological abnormalities in women in Gauteng Province, South Africa. S Afr Med J 
2013;103(5):313-317. DOI:10.7196/SAMJ.6514
15. South African HPV Advisory Board. Cervical cancer and human papillomavirus: South African 
guidelines for screening and testing. S Afr J Gynaecol Oncol 2010;2(1):23-26.
16. Crothers JW, Mount SL, Harmon M, Wegner E. The utility of human papillomavirus testing in young 
women with atypical glandular cells on Pap test. J Low Genit Tract Dis 2015;19(1):22-26. DOI:10.1097/
LGT.0000000000000044
17. Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC. Human papillomavirus DNA 
testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 2000; 92(10):818-825. 
DOI:10.1093/jnci/92.10.818
18. Einstein MH, Smith KM, Davis TE, et al. Clinical evaluation of the cartridge-based GeneXpert human 
papillomavirus assay in women referred for colposcopy. J Clin Microbiol 2014;52(6):2089-2095. 
DOI:10.1128/JCM.00176-14
Accepted 21 June 2016.
